Patents by Inventor Robert Rosa
Robert Rosa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240086982Abstract: Image-based parking recognition and navigation systems and methods are disclosed. An example method includes: obtaining camera data collected by the plurality of cameras, the image data identifying one or more parking locations; analyzing the camera data in accordance with one or more machine learning techniques to identify a plurality of candidate parking location, obtaining, from a smart phone app executed on a mobile user device, a user request to reserve a candidate parking location in the plurality of candidate parking location; determining a location of the candidate parking location based on location data associated with a first camera; identifying a booking method to reserve the candidate parking location based on the location of the candidate parking location; and responsive to obtaining the user request, enabling a user issuing the user request to reserve the candidate parking location through smart phone app executed on the mobile user device.Type: ApplicationFiled: November 14, 2023Publication date: March 14, 2024Inventors: Gianni Rosas-Maxemin, Robert Mazzola, Francisco Sandoval, Callam Poynter, Noah Kindler
-
Patent number: 11915587Abstract: The disclosed technology provides solutions for facilitating the selection of a parking space by a user of a parking application. A process of the disclosed technology can include steps for monitoring sensor data and location data associated with a user device, retrieving, based on the location data associated with a user device, listing data associated with one or more parking spaces in a vicinity of the user device, and capturing image data that includes at least a portion of the one or more parking spaces. In some aspects, the process may further include steps for overlaying one or more graphical objects onto the image data, wherein the one or more graphical objects are based on the listing data associated with the one or more parking spaces. Systems and machine-readable media are also provided.Type: GrantFiled: June 8, 2022Date of Patent: February 27, 2024Assignee: Pied Parker, Inc.Inventors: Gianni Rosas-Maxemin, Robert Mazzola, Francisco Sandoval
-
Patent number: 10105396Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.Type: GrantFiled: June 26, 2017Date of Patent: October 23, 2018Assignees: The Texas A&M University System, Temple Therapeutics, Inc.Inventors: Darwin J. Prockop, Joo Youn Oh, Barry Berkowitz, Gavin W. Roddy, Robert Rosa
-
Publication number: 20180236035Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.Type: ApplicationFiled: February 6, 2018Publication date: August 23, 2018Inventor: Robert Rosa
-
Publication number: 20180015124Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.Type: ApplicationFiled: June 26, 2017Publication date: January 18, 2018Inventors: Darwin J. Prockop, Joo Youn Oh, Barry Berkowitz, Gavin W. Roddy, Robert Rosa
-
Publication number: 20170266261Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.Type: ApplicationFiled: November 9, 2016Publication date: September 21, 2017Inventor: Robert Rosa
-
Patent number: 9730961Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.Type: GrantFiled: August 13, 2015Date of Patent: August 15, 2017Assignees: The Texas A&M University System, Temple Therapeutics, Inc., Scott & White HealthcareInventors: Darwin J. Prockop, Joo Youn Oh, Barry Berkowitz, Gavin W. Roddy, Robert Rosa
-
Patent number: 9498517Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.Type: GrantFiled: July 1, 2015Date of Patent: November 22, 2016Assignees: Scott & White Healthcare, The Texas A&M University SystemInventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
-
Publication number: 20160058795Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.Type: ApplicationFiled: August 13, 2015Publication date: March 3, 2016Inventors: Darwin J. Prockop, Joo Youn Oh, Barry Berkowitz, Gavin W. Roddy, Robert Rosa
-
Publication number: 20150374791Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.Type: ApplicationFiled: July 1, 2015Publication date: December 31, 2015Inventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
-
Patent number: 9090704Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.Type: GrantFiled: May 22, 2014Date of Patent: July 28, 2015Assignees: Scott & White Healthcare, The Texas A&M University SystemInventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
-
Patent number: 9062103Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.Type: GrantFiled: April 11, 2014Date of Patent: June 23, 2015Assignees: The Texas A&M University System, Temple Therapeutics, Inc., Scott & White HealthcareInventors: Darwin J. Prockop, Joo Youn Oh, Barry Berkowitz, Gavin W. Roddy, Robert Rosa
-
Publication number: 20140286914Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.Type: ApplicationFiled: May 22, 2014Publication date: September 25, 2014Applicants: Scott & White Healthcare, The Texas A&M University SystemInventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
-
Patent number: 8785395Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.Type: GrantFiled: May 3, 2011Date of Patent: July 22, 2014Assignees: The Texas A & M University System, Temple Therapeutics, Inc.Inventors: Darwin J. Prockop, Joo Youn Oh, Gavin W. Roddy, Robert Rosa, Barry A. Berkowitz
-
Patent number: 8759298Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.Type: GrantFiled: July 16, 2012Date of Patent: June 24, 2014Assignees: Scott & White Healthcare, The Texas A&M University SystemInventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
-
Publication number: 20130143814Abstract: The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.Type: ApplicationFiled: July 16, 2012Publication date: June 6, 2013Inventors: Robert Rosa, Gavin W. Roddy, Darwin J. Prockop
-
Publication number: 20130039924Abstract: The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.Type: ApplicationFiled: May 3, 2011Publication date: February 14, 2013Inventors: Darwin J. Prockop, Yoo Youn Oh, Gavin W. Roddy, Robert Rosa, Barry A. Berkowitz